[Federal Register Volume 66, Number 74 (Tuesday, April 17, 2001)]
[Notices]
[Page 19796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-9400]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 6, 2001, Novartis 
Pharmaceuticals Corporation, 59 Route 10, East Hanover, New Jersey 
07936, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
methylphenidate (1724), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to manufacture finished product for distribution to 
its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistance Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than June 18, 2001.

    Dated: April 6, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 01-9400 Filed 4-16-01; 8:45 am]
BILLING CODE 4410-09-M